Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01239121 · ClinicalTrials.gov registry record · NA

Regional Data Exchange to Improve Medication Safety

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
402
Enrollment target

NCT01239121: Completed NA study, sponsored by VA Office of Research and Development.

NCT01239121 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 402 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01239121, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
402 participants
Enrollment target

Study Summary

Medication reconciliation, a process by which a provider obtains and documents a thorough medication history with specific attention to comparing current and previous medication use, can prevent medication-related errors and harm. The aims of this study are: 1) To adapt medication reconciliation to include information from a computerized regional health information exchange (RHIO) in the Bronx, 2) To conduct a trial of the adapted medication reconciliation process and examine effects on medication errors, harm, and hospital costs, and 3) To identify factors that are barriers to adoption of the RHIO tool by James J. Peters (Bronx) VA providers. Findings from this project will provide an understanding of the effect of the RHIO tool on reducing harmful VA and non-VA medication use. It will also provide information on the feasibility of incorporating RHIO tool use into every day work flow for pharmacists and physicians.

Primary Outcome

Rating of potential for harm to patient from hospital medication discrepancies by record review. Minimum=0 Maximum=no maximum. Higher values represent increased detection of medication discrepancies. Although medication discrepancies are undesirable, increasing their detection might facilitate prevention of adverse drug events.

Interventions

  • OTHER HIE-Enhanced Medication Reconciliation
  • OTHER Optimal Medication Reconciliation without HIE

Trial Details

FieldValue
Enrollment Target 402 participants
Start Date 2012-02
Est. Completion 2016-06
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT01239121 record still lists

NCT01239121 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 2 interventions - of which HIE-Enhanced Medication Reconciliation is the first listed.

NCT01239121 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01239121 about?

NCT01239121 is a clinical study titled "Regional Data Exchange to Improve Medication Safety". Medication reconciliation, a process by which a provider obtains and documents a thorough medication history with specific attention to comparing current and previous medication use, can prevent medication-related errors and harm. The aims of this study are: 1) To adapt medication reconciliation to ...

What is the current status of trial NCT01239121?

This trial is currently completed. It is a NA study. The enrollment target is 402 participants. The study started on 2012-02. Estimated completion is 2016-06.

What interventions are being tested in trial NCT01239121?

The interventions under investigation include: HIE-Enhanced Medication Reconciliation (OTHER), Optimal Medication Reconciliation without HIE (OTHER).

Who is sponsoring clinical trial NCT01239121?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01239121's enrollment target sits among peer trials

402 245th of 2000 higher than 1,755 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04464226 · 402 participants · Phase 3

    Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

  • NCT05183763 · 402 participants · NA

    Medication Adherence Program

  • NCT06748222 · 402 participants · Phase 3

    E-Mindfulness Approaches for Living After Breast Cancer

  • NCT06896474 · 402 participants · NA

    SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01239121, the US trial registry maintained by the National Library of Medicine. NCT01239121 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.